Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.

Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases.

Following a Series B fundraise, and supported by both Scottish Enterprise and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.

We recently initiated a First-in-Human clinical oncology study with MDX-124, a monoclonal antibody with a unique target. It is the first drug to target annexin-A1, a protein in the immune system that plays a key role in inflammation and the development of numerous cancers, autoimmune conditions and other diseases.

Medannex won both ‘Investment of the Year’ and ‘Outstanding Skills Development’ at Scotland’s Life Sciences Annual Awards 2021.


 

Medannex is a proud signatory of the Scottish Business Pledge, showing our commitment to building sustainable growth whilst maintaining fairness, equality, opportunity and innovation.

more


Meet the Team


Latest News


“Medannex has identified a novel and promising target for immunotherapy, and I am delighted to offer guidance as the company prepares for its First-in-Human study.”

Dr Stefan Symeonides,
head of Phase I Trials at the CRUK Edinburgh Centre


Collaborations & Affiliations

Medannex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.